{"nctId":"NCT00281918","briefTitle":"Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia","startDateStruct":{"date":"2003-07"},"conditions":["Leukemia"],"count":817,"armGroups":[{"label":"Fludarabine+Cyclophosphamide+Rituximab (FCR)","type":"EXPERIMENTAL","interventionNames":["Drug: Rituximab","Drug: Cyclophosphamide","Drug: Fludarabine Phosphate"]},{"label":"Fludarabine+Cyclophosphamide (FC)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclophosphamide","Drug: Fludarabine Phosphate"]}],"interventions":[{"name":"Rituximab","otherNames":[]},{"name":"Cyclophosphamide","otherNames":[]},{"name":"Fludarabine Phosphate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosed B-cell chronic lymphocytic leukemia (CLL) defined by the National Cancer Institute (NCI) Working Group criteria\n* Meets 1 of the following criteria:\n\n  * Binet stage C disease\n  * Binet stage B disease AND ≥ 1 of the following signs or symptoms\\*:\n\n    * B symptoms (night sweats, weight loss ≥ 10% within the previous 6 months, fevers \\> 38°C or 100.4°F for ≥ 2 weeks without evidence of infection), or constitutional symptoms (fatigue)\n    * Continuous progression (doubling of peripheral lymphocyte count within the past 6 months and absolute lymphocyte count \\> 50 G/I)\n    * Evidence of progressive marrow failure as manifested by the development/worsening of anemia and/or thrombocytopenia\n    * Massive, progressive or painful splenomegaly or hypersplenism\n    * Massive lymph nodes or lymph node clusters (\\> 10 cm in longest diameter), danger of organ complications through large lymphoma (e.g., vascular compression or tracheal narrowing), or progressive lymphadenopathy\n    * Occurrence of symptomatic hyperviscosity problems at leukocyte counts \\> 200 G/I (symptomatic leukostasis) NOTE: \\* Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease is not sufficient for eligibility\n* No Binet stage A disease\n* No transformation to an aggressive B-cell malignancy (e.g., diffuse large cell lymphoma, Richter's syndrome, or prolymphocytic leukemia)\n\nPATIENT CHARACTERISTICS:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Cumulative Illness Rating Scale (CIRS) score \\> 6\n* Life expectancy \\> 6 months\n* Bilirubin ≤ 2 times upper limit of normal (ULN)\n* Alkaline phosphatase and transaminases ≤ 2 times ULN\n* Creatinine clearance ≥ 70 mL/min\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 2 months after study treatment\n* No known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the study drugs\n* No cerebral dysfunction that precludes chemotherapy\n* No active bacterial, viral, or fungal infection\n* No clinically significant autoimmune cytopenia or Coombs-positive hemolytic anemia\n* No other active malignancy requiring concurrent treatment except basal cell carcinoma or tumors treated curatively by surgery\n* No medical or psychological condition that would preclude study therapy\n* No concurrent disease that requires prolonged (\\> 1 month) therapy involving glucocorticoids\n\nPRIOR CONCURRENT THERAPY:\n\n* No previous treatment of CLL by chemotherapy, radiotherapy, or immunotherapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS)","description":"Progression-free survival (PFS) was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"981.0","spread":null},{"groupId":"OG001","value":"1212.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival (EFS)","description":"Event-free survival (EFS) was defined as the time between randomization and the date of disease progression, relapse, start of new CLL treatment or death by any cause.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"947.0","spread":null},{"groupId":"OG001","value":"1212.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the time between randomization and the date of death due to any cause. Median OS was not reached.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1373","spread":null},{"groupId":"OG001","value":"1372","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival (DFS) of Patients With Confirmed Complete Response (CR).","description":"CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. DFS was calculated from time of CR to relapse or death. Median DFS was not reached.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1164","spread":null},{"groupId":"OG001","value":"1226","spread":null}]}]}]},{"type":"PRIMARY","title":"Final Analysis: Time to Progression-free Survival Event","description":"Progression-free survival was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"998.0","spread":null},{"groupId":"OG001","value":"1703.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Final Analysis: Time to Overall Survival Event","description":"Overall survival (OS) was defined as the time between randomization and the date of death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2613.0","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Final Analysis: Time to Event-free Survival Event","description":"Event-free survival was defined as the time between randomization and the date of disease progression, relapse, start of new Chronic Lymphocytic Leukemia treatment or death by any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"951.0","spread":null},{"groupId":"OG001","value":"1666.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Final Analysis: Time to Disease-free Survival (DFS) Event in Participants With Complete Response (CR)","description":"CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. DFS was calculated from time of CR to relapse or death","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1488.0","spread":null},{"groupId":"OG001","value":"1854.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Final Analysis: Duration of Response","description":"Duration of response was defined as the time from the first documented Complete Response, Partial Response to disease progression or death by any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1102.0","spread":null},{"groupId":"OG001","value":"1718.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Final Analysis: Percentage of Participants With Complete Response (CR) and Partial Response","description":"CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. Partial response is defined as a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"85.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Final Analysis: Time to New Treatment for Chronic Lymphocytic Leukemia(CLL)","description":"The time from randomization to the start of a new treatment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1455.0","spread":null},{"groupId":"OG001","value":"2082.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":164,"n":398},"commonTop":["Neutropenia","Leukopenia","Thrombocytopenia"]}}}